MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. by Ratti, M et al.
Vol.:(0123456789)
Targeted Oncology 
https://doi.org/10.1007/s11523-020-00717-x
REVIEW ARTICLE
MicroRNAs (miRNAs) and Long Non‑Coding RNAs (lncRNAs) as New 
Tools for Cancer Therapy: First Steps from Bench to Bedside
Margherita Ratti1,2,3 · Andrea Lampis1,2 · Michele Ghidini4 · Massimiliano Salati1,2 · Milko B. Mirchev5 · 
Nicola Valeri1,2,6 · Jens C. Hahne1,2 
 
© The Author(s) 2020
Abstract
Non-coding RNAs represent a significant proportion of the human genome. After having been considered as ‘junk’ for a 
long time, non-coding RNAs are now well established as playing important roles in maintaining cellular homeostasis and 
functions. Some non-coding RNAs show cell- and tissue-specific expression patterns and are specifically deregulated under 
pathological conditions (e.g. cancer). Therefore, non-coding RNAs have been extensively studied as potential biomarkers in 
the context of different diseases with a focus on microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) for several 
years. Since their discovery, miRNAs have attracted more attention than lncRNAs in research studies; however, both families 
of non-coding RNAs have been established to play an important role in gene expression control, either as transcriptional or 
post-transcriptional regulators. Both miRNAs and lncRNAs can regulate key genes involved in the development of cancer, 
thus influencing tumour growth, invasion, and metastasis by increasing the activation of oncogenic pathways and limiting 
the expression of tumour suppressors. Furthermore, miRNAs and lncRNAs are also emerging as important mediators in 
drug-sensitivity and drug-resistance mechanisms. In the light of these premises, a number of pre-clinical and early clinical 
studies are exploring the potential of non-coding RNAs as new therapeutics. The aim of this review is to summarise the 
latest knowledge of the use of miRNAs and lncRNAs as therapeutic tools for cancer treatment.
1 Introduction
Non-coding RNAs are a large family of RNAs that are 
not coding for known proteins. In general, non-coding 
RNAs can be classified according to their length into 
small (< 200 nucleotides) and long (> 200 nucleotides) 
RNAs or according to their function as housekeeping and 
regulatory RNAs [1]. About 17 categories of non-coding 
RNA molecules have been identified so far; among them 
transfer RNAs, ribosomal RNAs, small nucleolar RNAs, 
endogenous small interfering RNAs, sno-derived RNAs, 
transcription initiation RNAs, microRNA-offset-RNAs, 
circular RNAs, vault RNAs, microRNAs (miRNAs), small 
interfering RNAs (siRNAs), small nuclear RNAs, extra-
cellular RNAs, piwi-interacting RNAs, small Cajal body 
RNAs, long intergenic non-coding RNAs and long non-
coding RNAs (lncRNAs) are known [2–23]. Non-coding 
RNAs constitute the majority of the human genome and 
retain fundamental biological properties within cells [24, 
25]. Among their functions, they regulate transcription, 
influence translation of coding genes, are components of 
the protein synthesis machinery, and regulate each other, 
e.g. modify ribosomal RNAs, and lncRNAs can counteract 
miRNAs by sequestering them (miRNA sponges) [17, 26]. 
Moreover, many physiological processes are regulated by 
non-coding RNAs, including development, gametogenesis, 
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stress, immune response and tumourigenesis [17, 27]. 
MicroRNAs may also influence longevity as was shown 
by analysing the lifespan of the roundworm Caenorhabdi-
tis elegans [28]. In this particular case, a loss-of-function 
mutation in the lin-4 miRNA down-regulated FOXO/DAF-
16 and up-regulated lin-14, resulting in a shorter lifespan 
[27].
Long non-coding RNAs and miRNAs are the most stud-
ied classes of non-coding RNAs involved in pathological 
conditions [13, 29, 30]. This review aims to focus on the 
different functions of lncRNAs and miRNAs and on their 
potential utility as therapeutic targets.
2  MicroRNAs
MicroRNAs are short RNA transcripts of 18–24 nucle-
otides and they regulate gene expression at the transla-
tional level [14]. They are among the most extensively 
studied and best characterised non-coding RNAs. Accord-
ing to the canonical view, miRNAs are regarded as nega-
tive regulators of gene expression that upon binding to 
the 3ʹ-untranslated region of the target messenger RNA 
(mRNA) cause a block of translation and/or degradation 
of the transcript, therefore down-regulating the final pro-
tein synthesis rate [31]. However, novel non-conventional 
mechanisms of action have been suggested for miRNAs 
that challenge traditional paradigms. For instance, in 
contrast to the general consensus that miRNA-mRNA 
interactions occur in the cytoplasm, miR-29b has been 
demonstrated to localise predominantly in the nucleus 
[32]. Furthermore, some miRNAs (like miR-10) can exert 
their effects also by binding to the 5ʹ-untranslated region 
[33] or like miR-155 to the coding sequence of target 
mRNAs [34]. Sometimes miRNAs can affect translation 
by up-regulation mechanisms. It has been shown that miR-
369-3p recruits a protein complex to the AU-rich elements 
in the tumour necrosis factor-alpha mRNA and induces an 
increase of the tumour necrosis factor-alpha translation 
rate [35].
A single miRNA can target several mRNAs, thus each 
miRNA can simultaneously regulate multiple target genes, 
both within a single pathway or even across different path-
ways [36–38]. For example, while the miR-17 family targets 
various components of the transforming growth factor-beta 
(TGF-β) signalling pathway, including TGF-β receptors 
and down-stream transducers such as SMADs and cyclin-
dependent kinase inhibitor 1A [39], miR-21 suppresses key 
genes of major tumour suppressive pathways such as p53, 
TGF-β and mitochondrial apoptosis [40].
MicroRNA expression patterns are tissue specific [41] 
and often define the physiological nature of the cell [42]. 
Numerous publications show that altered mRNA expression 
in the context of several diseases (e.g. cancer, viral diseases, 
cardiovascular diseases, neurodegenerative and immune-
related diseases) is caused by deregulation of miRNA 
expression [13, 43–48].
MicroRNA dysfunction occurs as a consequence of 
diverse mechanisms such as promoter methylation, muta-
tions, amplifications or deletions involving miRNA cod-
ing regions, transcriptional regulation by proteins (e.g. p53 
and c-myc) or lncRNAs, and down-regulation as well as 
mutations in genes coding for miRNA biogenesis-related 
enzymes (i.e. Drosha, Exportin 5, Dicer, Argonaute 2) [31, 
49–51].
Multiple lines of evidence suggest that tissue- and dis-
ease-specific miRNA signatures may be used as biomark-
ers for diagnostic, prognostic and predictive purposes in 
the clinic [46, 52–58]. However, the most exciting avenue 
of current translational research efforts is focusing on their 
therapeutic potential [59–64]. Indeed, their pivotal role in a 
huge range of pathological conditions together with the fact 
that a single miRNA can modulate the expression of several 
genes across multiple pathways altered in diseases makes 
them attractive therapeutic targets [65]. Modulation of the 
expression of miRNAs could be a novel and promising ther-
apeutic modality that can be achieved through administra-
tion of either miRNA mimics to restore expression of down-
regulated miRNAs or miRNA inhibitors (anti-miRNA) to 
counteract the up-regulation of pathogenic miRNAs [66]. 
Research on miRNAs as both targets and therapeutics is 
proceeding at a rapid pace. In less than 20 years after the 
discovery of the first miRNA in the nematode C. elegans 
[67, 68], the first miRNA-based therapeutic entered clinical 
evaluation in patients with chronic hepatitis C virus (HCV) 
genotype 1 infection [69]. Owing to a deeper understand-
ing of disease-relevant miRNAs and advances in in-vivo 
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delivery systems, the administration of miRNA-based thera-
peutics has recently shown to be feasible and safe in humans 
with encouraging efficacy results in early-phase clinical tri-
als (Table 1) [69–71].
However, although a plethora of miRNA-based com-
pounds have been investigated in preclinical studies, only a 
minority of these has moved to clinical development. Chal-
lenges concerning a proper target selection, stability in body 
fluids, and specificity of target binding as well as off-target 
effects remain to be addressed in the future to optimise the 
in-vivo delivery and efficiency of miRNA-based therapeu-
tics. As miRNAs are implicated in virtually all physiological 
and pathological processes, a huge therapeutic potential is 
expected from miRNA-based constructs.
Interestingly, in addition to acting within cells, circulat-
ing cell-free miRNAs have been detected in plasma, serum, 
urine, and many other body fluids and have been shown 
to act at distant sites within the body [72, 73]. It has been 
recently shown that miRNAs can be either released by pas-
sive leakage from lytic cells or actively secreted via extra-
cellular vesicles (e.g. exosomes) as well as via high-density 
lipoprotein [74, 75]. Still, another significant proportion of 
extracellular miRNAs is exported in conjunction with RNA-
binding proteins, such as AGO2 and NPM1 [76–78]. Of 
note, this horizontal transfer of secreted miRNA is emerg-
ing as a new form of intercellular communication, by which 
a donor can influence the gene expression of a recipient cell, 
both in an autocrine and paracrine manner [79, 80]. More 
importantly, besides the tremendous contribution to the 
understanding of mechanisms governing cell-to-cell signal-
ling and miRNA functions, the evidence of a microvesicle-
dependent miRNA trafficking system provides intriguing 
insights for the development of efficient miRNA delivery 
systems for targeted therapeutics.
Table 1  Clinical trials investigating microRNA therapeutics in cancer and other diseases
ATLL adult T-cell leukemia/lymphoma, CLL chronic lymphocytic leukemia, DBCLC diffuse large B-cell lymphoma, GalNAc N-acetylgalactosa-
mine, HCC hepatocellular carcinoma, HCV hepatitis C virus, NAFLD non-alcoholic fatty liver disease, NSLC non-small cell lung cancer, RCC 
renal cell carcinoma, SCLC small-cell lung cancer, TCL T-cell lymphoma
Drug name Type Disease Phase Status ClinicalTrials.
gov identifier
Miravirsen Anti-mir122 HCV I Completed NCT01646489
Miravirsen Anti-mir122 HCV II Completed NCT02508090
Miravirsen Anti-mir122 Treatment naïve
HCV
II Completed NCT01200420
Miravirsen Anti-mir122 HCV II Completed NCT02452814
Miravirsen Anti-mir122 HCV II Completed NCT01200420
Miravirsen Anti-mir122 HCV II Active NCT01727934
Miravirsen Anti-mir122 Refractory HCV II Active NCT01872936
RG-101 GalNAc-conjugated anti-mir122 HCV Ib Terminated
MesomiR miR-16 mimic Malignant pleural mesothelioma, 
NSCLC
I Completed NCT02369198
MRX34 miR-34 mimic Primary HCC, melanoma, RCC, 
SCLC, NSCLC, lymphoma, 
multiple myeloma
I Terminated NCT01829971
MRX34 miR-34 mimic Melanoma I Terminated NCT02862145
MRG-106 Anti-miR155-5p Cutaneous TCL, mycosis fungoi-
des, CLL, DLBCL, ATLL
I Recruiting NCT02580552
MRG-106 Anti-miR155-5p Cutaneous TCL, mycosis fungoides II Recruiting NCT03713320
MRG-106 Anti-miR155-5p Cutaneous TCL, mycosis fungoides II Not yet recruiting NCT03837457
RG-125 GalNAc-conjugated anti-
miR-103/107
Type 2 diabetes mellitus and 
NAFLD
I/IIa Suspended (sponsor decision) NCT02826525
MRG-201 miR-29 mimic Keloids I Completed NCT02603224
MRG-201 miR-29 mimic Keloids II Recruiting NCT03601052
EXTH-61 Anti-miR-10 Glioblastoma I Recruiting NCT01849952
MRG-110 Anti-miR-92 Small skin wound I Completed NCT03603431
RG-012 Anti-miR-21 Alport’s syndrome I Active NCT03373786
RG-012 Anti-miR-21 Alport’s syndrome II Suspended (sponsor decision) NCT02855268
pSil-miR200 miR-200a/c plasmid Inflammation and osteogenesis 
after tooth extraction
I Not yet recruiting NCT02579187
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3  Long Non‑Coding RNAs
Long non-coding RNAs are constituted by more than 200 
nucleotides and have an important role as regulators dur-
ing development and pathological processes [81–85]. Under 
physiological conditions, most lncRNAs are transcribed 
from promoters with low CpG dinucleotide contents and 
therefore expressed at low levels [86]. An aberrant expres-
sion of lncRNAs in several diseases is due to modulation of 
the chromatin state. Changes in chromatin structure can also 
be induced by miRNAs; one example is the up-regulated 
expression of lncRNA MEG3 by miRNA-29 via its inhibi-
tion of DNA methyltransferase activity that in turn hampers 
the methylation of the MEG3 promoter in the context of 
hepatocellular cancer [87].
Long non-coding RNAs can be localised in the nucleus 
or cytoplasm [88, 89]. Often lncRNAs have been shown to 
serve as scaffolds for the assembly of multiple component 
complexes [90]. Depending on the subcellular localisation of 
the lncRNAs, they directly regulate gene expression by (a) 
influencing chromatin modification by binding to chroma-
tin regulatory proteins; (b) regulating splicing and stability 
of mRNAs; as well as (c) indirectly in transcriptional and 
post-transcriptional gene expression mechanisms by inter-
acting with other RNAs and proteins [91–93]. For instance, 
several lncRNAs (e.g. MALAT1, H19, MEG3) are important 
regulators of the cell cycle via their influence on p21 or p53 
[94–96]. On the contrary, some lncRNAs (e.g. H19, PINT, 
RP11–467J12.4, LincRNA-p21, PANDA) are induced by p53 
[97–101].
Several reports have underlined the fundamental inter-
action between lncRNAs and miRNAs in RNA regulation 
processes [13, 29, 102, 103]. Long non-coding RNAs can act 
as miRNA decoys by sequestering miRNAs, thus acting as 
competing endogenous RNAs and leading to re-expression 
of miRNA target genes [13, 102, 103]. In addition, lncR-
NAs can promote gene expression by competing with miR-
NAs for specific binding sites in the non-coding regions of 
mRNAs and preventing the transcriptional repression caused 
by miRNAs [29, 102, 103]. The fact that some lncRNAs can 
be processed into miRNAs highlights the strong interaction 
among different classes of non-coding RNAs [13, 29, 102, 
103].
Many lncRNAs are expressed in a tissue- and cell type-
specific manner; the expression varies between different 
development stages and they are often deregulated in a 
disease-specific pattern [104–107] and changes in lncRNA 
expression has been observed in body fluids such as urine 
and blood in several pathological conditions [108–110]. 
Long non-coding RNAs are released either encapsulated 
in exosomes or inside apoptotic bodies and they are bound 
to RNA-binding proteins [111, 112]; therefore, they are 
resistant against RNase degradation and they could be of 
interest as non-invasive biomarkers [108, 113].
Altered lncRNA expression has been observed in several 
diseases and especially in cancer [114]. Because of the abil-
ity of lncRNAs to interact with DNA, RNA, proteins and 
their combination, lncRNAs have the potential to contribute 
to the onset of cancer, modulating virtually all hallmarks of 
cancer and fostering cancer progression.
Long non-coding RNAs were shown to respond to DNA 
damage and to be involved in DNA repair; for instance, 
estrogen-regulated lncRNAs CUPID1 and CUPID2 trigger 
progression of breast cancer by an inhibition of cell-cycle 
arrest following DNA damage [115]. In triple-negative 
breast cancer, lncRNA LINK-A increases the stability of 
hypoxia-inducible factor 1-alpha [116] and, in oral cancer, 
lncRNA HIFCAR was identified as a hypoxia-inducible 
factor 1-alpha co-activator [117]. In both cases, lncRNAs 
support tumour growth by regulating the Warburg effect. In 
a hypoxic environment, the expression of some lncRNAs 
(e.g. lncRNA LET) is also repressed for instance by his-
tone deacetylase 3 activity, resulting in a reduced histone 
acetylation rate of the lncRNA promoter region [118]. Low 
lncRNA LET expression is also an important prerequisite for 
stabilisation of nuclear factor 90 protein that in turn results 
in increased cancer invasion [118]. In renal tumours, the 
down-regulation of tumour suppressor lncRNA FILNC1 
increases c-Myc expression and in parallel enhances glu-
cose metabolism and lactic acid production [119]. Moreover, 
epithelial-mesenchymal transformation (EMT) is under the 
influence of lncRNAs as demonstrated for the up-regulated 
expression of zinc finger proteins ZEB1 and ZEB2 fol-
lowing loss of lncRNA ATB in hepatocellular carcinoma, 
which leads to increased distant metastasis [120]. In con-
trast, hepatitis B virus X protein down-regulates lncRNA 
hDREH, an inhibitor of EMT in hepatocellular carcinoma 
[121]. Another lncRNA that promotes EMT and metastasis 
in various tumours such as liver cancer, pancreatic cancer 
and breast cancer is HOTAIR [122–124]. Expression of 
HOTAIR in cancer cells is induced by TGF-β secreted by 
carcinoma-associated fibroblasts [125]. HOTAIR in turn 
induces EMT by activating the SMAD cascade signalling 
in tumour cells [125].
Recently, lncRNAs have been identified as important 
regulators for the tumour immune micro-environment 
[126–130], as for instance, the immune escape of liver 
tumours by lncRNA epidermal growth factor receptor 
(EGFR)-dependent stimulation of regulatory T-cell differ-
entiation [131]; other reports have evidenced the regulation 
of macrophage recruiting into bladder cancer by lncRNA 
LNMAT1 [132] and lncRNA NKILA by enhancing sensi-
tivity of tumour-specific cytotoxic T lymphocytes and type 
1 helper T cells to activation-induced cell death and by 
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inhibiting the nuclear factor-κB signalling pathway [133]. 
All of this activity clearly shows the deep relevance of lncR-
NAs in the regulation of cancer from initiation to progres-
sion but also in the mantainance of the micro-enviroment 
needed to support cancer invasion and escape to metastatic 
sites. Long non-coding RNAs are contributing to all levels in 
cancer development and they could potentially be exploited 
for treatments.
4  Use of MicroRNAs and Long Non‑Coding 
RNAs as Clinical Biomarkers
MicroRNA and lncRNA expression patterns are known to 
vary under pathological conditions. In addition, non-cod-
ing RNAs can be detected in tissue samples as well as in 
all body fluids such as blood (plasma/serum), urine, cer-
ebrospinal fluid or tears [134]. MicroRNAs, especially, are 
very stable even in RNAse-rich biofluids thus making them 
potential new biomarkers [73]. Furthermore, miRNAs and 
lncRNAs are present also in exosomes, which protect them 
from degradation within body fluids [135]. Therefore, tis-
sues as well as liquid biopsies can be used as starting mate-
rial for exploring the potential of both non-coding RNA 
classes as biomarkers and they are already widely used as 
biomarkers in cardiac and neural diseases as well as cancer 
[13, 53, 105, 136–138].
An increased level of circulating miR-1 has been shown 
to be a promising biomarker for acute myocardial infarc-
tion [139] and miR-208a/b along with miR-499 have been 
demonstrated as potential biomarkers of the severity of an 
infarction and the degree of myocardial damage [140]. A 
panel of ten miRNAs in plasma has been used to predict 
the individual risk for future fatal acute myocardial infarc-
tion in healthy individuals, resulting in nearly 80% correct 
risk assessment [141] and furthermore expression levels of 
lncRNAs (ZFAS1 and CDR1AS) are also able to predict 
myocardial infarction [142].
In the context of neurological diseases, the power of a 
diagnostic based on non-coding RNAs present in biologi-
cal fluid is a great advance given that the disease site is 
largely inaccessible. Disease-specific neural lncRNAs can 
be detected in the blood of patients with Alzheimer’s disease 
[143] and patients with major depressive disorder [144].
MicroRNA-based assays can be used for diagnostic and 
prognostic purposes in the setting of different cancers; e.g. 
miRNA expression profiling is clinically used as a tool to 
distinguish between molecular subtypes of breast cancer 
[145] and different forms of lung cancer [146]. Another 
assay composed of 64 miRNAs can detect the primary tis-
sue of origin for 49 tumour types with very high accuracy 
and is an offered laboratory test [147, 148].
In addition, miRNA- and lncRNA-based assays are often 
used in combination with existing protein biomarkers to 
improve the specificity and sensitivity of the diagnosis. One 
example is given by the lncRNA PCA3-based test from urine 
samples for the detection of prostate cancer [149], which has 
US Food and Drug Administration approval. By including 
lncRNA PCA3 in prostate cancer diagnosis, the sensitivity 
and accuracy are significantly increased in comparison to 
using the protein biomarker PSA alone [150, 151]. Further-
more, expression patterns of miRNAs and lncRNAs could be 
used to monitor therapy success and drug resistance develop-
ment [13] and therefore they are being tested as biomarkers 
in several registered clinical studies (ClinicalTrials.gov) to 
monitor disease progression in patients receiving Food and 
Drug Administration-approved drugs; e.g. NCT02656589 
(prognosis of Herceptin®-treated patients with breast can-
cer), NCT02471469 (identification of enzalutamide-treated 
patients with prostate cancer with need of a further surgery) 
and NCT02243592 (analysing miRNA expression in tis-
sue samples from patients with cancer who are exceptional 
responders to treatment).
5  Identification of Deregulated Non‑Coding 
RNAs
The identification of non-coding RNA candidates for design-
ing targeted strategies is the foremost step in developing non-
coding RNA-based therapeutics. This requires translational 
research efforts starting with a patient’s sample analysis to 
select disease-specific non-coding RNAs more likely to be 
of biological relevance to a given pathological condition. 
The advent of high-throughput technologies along with mas-
sive parallel sequencing analysis have tremendously facili-
tated the search for non-coding RNAs, especially for key 
regulatory miRNAs, which could be targeted. To this end, 
genome-wide functional screening studies using libraries 
of hundreds of miRNA mimics or inhibitors are among the 
most commonly employed approaches [152]. For instance, 
a recent report described the genome-wide data, including 
miRNAs, isolated from extracellular vesicles of liver cancer 
cell lines [153]. On a different approach, several publicly 
available repositories exist that link genomic, transcriptomic 
and proteomic data of coding genes and non-coding RNAs 
targeting these genes, thus assisting researchers in identify-
ing the most biologically relevant lncRNAs and miRNAs in 
a disease-specific context. In fact, databases such as LncR-
NADisease [154], lncRNASNP [155], miRTarbase [156] 
and StarBase [157] contain thousands of experimentally 
validated and continuously updated lncRNA- or miRNA-
target interactions including data generated by cutting-edge 
techniques such as crosslinking immunoprecipitation [158, 
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159]. In addition, the matching of these data with those com-
ing from prediction platform such as TargetScan [160] has 
the potential to further improve the accuracy of the search 
for relevant non-coding RNAs.
6  Non‑Coding RNA‑Based Therapeutics 
in Cancer: Principles, Promises 
and Challenges
The ability to target and modulate multiple protein-coding 
genes at different levels of the same pathways or across dif-
ferent pathways in virtually all pathological processes makes 
non-coding RNAs, especially miRNAs, therapeutic candi-
dates [64, 104, 105, 161]. This offers several advantages 
including the simultaneous targeting of various compensa-
tory pathways involved in the development of therapy resist-
ance as well as the chance to hit commonly undruggable 
proteins via their miRNA regulators.
Some promising approaches aimed at manipulating 
miRNA expression are summarised in Fig. 1. Expression 
levels of miRNAs can be regulated by anti-miRNAs and 
miRNA mimics. Anti-miRNAs are synthetic single-stranded 
RNA molecules that owing to sequence complementary bind 
and sequester mature miRNAs and by this activity counter-
act up-regulated miRNAs [61]. In contrast, miRNA mimics 
are synthetically derived oligonucleotide duplexes, which, 
upon introduction into the cells, behave similarly to (and 
therefore mimic) endogenous miRNAs and they are able 
to restore expression of down-regulated miRNAs [66]. A 
limitation of this approach could be the ability of cancer 
cells to overcome miRNA-mediated repression by allowing 
mutations within miRNA response elements or expressing 
mRNA isoforms with shorter 3ʹ-untranslated regions lacking 
miRNA-binding sites by using alternative cleavage and poly-
adenylation [162–165]. The missing repressive elements in 
mRNA isoforms will then prevent miRNA mimics binding 
and result in therapy failure. Another strategy to therapeuti-
cally fine tune miRNA levels relies on small-molecule com-
pounds [166, 167] that can perturb several steps of miRNA 
biogenesis and function mainly through transcriptional regu-
lation [168–170]. For instance, azobenzene was identified as 
a potent and specific inhibitor of miR-21 expression during a 
large-scale drug screening on small organic molecules [170]. 
Azobenzene affects the transcription of the miR-21 gene into 
pri-miR-21 and is an example for targeting the miRNA syn-
thesis pathway in the nucleus [170].
Other small-molecule modifiers act on miRNAs in the 
cytoplasm as it was shown for the liver-specific miR-122. 
Some small molecules act either as miR-122 inhibitors (e.g. 
can be used for blocking HCV replication in liver cells) or 
as miR-122 activators leading to increased apoptosis in HCC 
cell lines [171]. Furthermore, DICER and AGO2, two main 
components interacting with the RISC complex and respon-
sible for the formation of mature miRNAs in the cytoplasm, 
may be potential targets for interfering with miRNA biosyn-
thesis [172]. In addition, it is possible to block the release of 
exosomes and other microvesicles [173, 174] that are known 
carriers of proteins and genetic material including miRNAs 
between cells [175–177]. Furthermore, the use of vector-
based strategies has been successfully adopted both in in-
vitro and in-vivo models for targeting miRNAs [178]. This 
approach is based on the expression of specific lncRNAs 
acting like sponges or decoys capable of selectively seques-
tering miRNAs by means of various miRNA-binding sites. 
As an ultimate result, miRNA down-stream target genes are 
de-repressed and actively transcribed.
Therapeutic targeting of lncRNA expression can be 
reached by different approaches (Fig. 2) that have to be 
adapted to the different sub-cellular localisation of lncR-
NAs. Nuclear-located lncRNAs can be targeted by chemi-
cally modified antisense oligonucleotides (ASOs) resulting 
in RNAseH-dependent degradation [179]. Furthermore, 
ASOs or small-molecule inhibitors can be used to inhibit 
lncRNA-RNA-binding protein interactions [180]. However, 
the limitations of ASO use has also been recently described. 
Specifically, it was demonstrated that ASO-mediated cleav-
age of nascent RNAs can induce premature transcription 
termination [181]. The introduction of ASOs results in a 
reduction in polymerase II occupancy down-stream of the 
transcript cleavage site in an exonuclease XRN2-dependent 
manner and by this activity influence transcription in general 
[181]. Nevertheless, it seems possible to target the 3′-end of 
transcripts with ASOs to reach RNA knock-down without 
disturbing polymerase II association with the distal gene 
body [181] and this must be taken into account for thera-
peutic use of ASOs. Long non-coding RNA expression has 
been also modulated via steric blocking of the promoter 
or by using genome-editing techniques such as CRISPR/
Cas9 [182–184]. Up-regulation of lncRNA expression can 
be mediated by knock-down of the relevant corresponding 
natural antisense transcripts [185]. In contrast, lncRNAs pre-
sent in the cytoplasm can be degraded with siRNA-based 
strategies involving the multiprotein complex RISC, RNAse 
dicer and endonuclease Argonaut2-dependent degradation 
pathway [122, 186, 187].
However, naked oligonucleotides per se, regardless if 
single or double stranded, display suboptimal pharma-
cokinetic and pharmacodynamic properties owing to their 
molecular size (> 6000 Da) and the negatively charged 
backbone [188]. Indeed, in-vivo stability, cell permeabil-
ity, tissue-specific targeting and potential off-target effects 
represent hurdles to be overcome to successfully translate 
RNA-based compounds from the bench to the bedside.
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7  Chemical Modification and Encapsulation 
into Delivery Vehicles
One of the greatest challenges related to in-vivo RNA 
therapeutic delivery to the target tissue is represented 
by their stability in body fluids. As already mentioned, 
naked oligonucleotides are subject to degradation by 
nucleases, especially 2′-hydroxyl-dependent RNAses, 
both in serum and in the endosomal compartment [189]. 
To overcome this issue and provide higher stability to 
RNA therapeutics, two complementary and non-mutually 
exclusive approaches have been adopted. The first one 
is based on chemical modifications mostly affecting the 
Fig. 1  Illustration of the multi-step microRNA (miRNA) biogenesis 
pathways, miRNA-target messenger RNA (mRNA) interaction and 
the exosome-mediated miRNA secretion pathway along with relative 
druggable concentrations. Black arrows refer to enzymatic steps, blue 
arrows refer to therapeutic approaches enhancing miRNA expression, 
while red lines refer to therapeutic approaches blocking miRNA func-
tions. For details see the main text
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2ʹ-position of the sugar ring of the RNA backbone that 
include the incorporation of O-methyl and O-methyoxy-
ethyl groups or phosphorothioate-like groups and locked 
nucleic acid (LNA) modifications (2′,4′-methylene link-
age of the ribose) that also improve the binding capacity 
for complementary sequences [190, 191]. The other strat-
egy involves the adoption of delivery technologies that 
in addition to protecting RNA from nucleases can also 
increase the delivery rate to disease-related tissues [192]. 
Administered antisense oligonucleotides have been found 
to accumulate and control gene expression in the liver and 
kidneys of patients but targeting of other tissues was less 
effective [193, 194].
Often RNA therapeutics are encapsulated into nanopar-
ticle vehicles to overcome these limitations [195]. Among 
them, lipid-based systems such as neutral lipid emulsions 
and polymers such as polyethylene glycol and polyethyl-
enimine are the most commonly tested delivery vehicles in 
both pre-clinical and clinical studies [196, 197]. However, 
potential immunostimulatory effects and a suboptimal 
specificity to a targeted disease site need to be overcome 
to successfully exploit miRNA therapeutics into the clinic.
A strategy to prevent harmful side effects caused by the 
delivery vehicle is to link RNA therapeutics to a ligand 
whose receptor is over-expressed on cancerous cells and 
deliver it directly into tumour cells [198]. Such a targeted 
delivery was successfully used in in-vitro and in-vivo studies 
with lung and breast tumour models by fusing miRNAs to 
folate where FolamiRs were taken up by tumour cells over-
expressing the folate receptor in comparison to normal tissue 
Fig. 2  Illustration of the possibilities to target and alter the expres-
sion level of long non-coding RNAs (lncRNAs). a Nuclear localised 
lncRNAs can be targeted by chemically modified antisense oligonu-
cleotides (ASOs) resulting in RNAseH-dependent degradation. b 
Antisense oligonucleotides or small-molecule inhibitors can be used 
to inhibit the lncRNA-RNA-binding protein interactions. c Long non-
coding RNA expression can be modulated via steric blocking of the 
promoter or by using genome-editing techniques such as CRISPR/
Cas9 [182–184]. d Up-regulation of lncRNA expression can be medi-
ated by knock-down of the relevant corresponding natural antisense 
transcripts (NATs). e Long non-coding RNAs present in the cyto-
plasm can be degraded with small interfering RNA (siRNA)-based 
strategies involving the multiprotein complex RISC, RNAse dicer and 
endonuclease Argonaut2-dependent degradation pathway
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[198–202]. One limitation of this approach is most probably 
the endocytic uptake of folate derivate and entrapment of 
FolamiRs into the endosomal compartment [198].
Interestingly, exosomes that are extracellular cell-derived 
phospholipid nanovescicles horizontally transmitting bio-
active molecules to specific recipient cells are increasingly 
regarded as natural nanocarriers for miRNA- and lncRNA-
based therapeutic delivery [203]. Indeed, exosomes are 
endowed with target-homing specificity, stability and capa-
bility of surmounting in-vivo barriers that can lead to spe-
cific and efficient delivery of molecules including nucleic 
acids [204]. In an elegant in-vivo study, human embryonic 
kidney cells were transfected with the exogenous tumour 
suppressor let-7a, and after purification from the culture 
supernatant, let-7a-containing exosomes were systemically 
administered to mice bearing a EGFR-expressing breast 
cancer xenograft [205]. The authors were able to show that 
exosomes loaded with let-7a successfully achieved targeted 
delivery and tumour regression, providing a proof of princi-
ple on the feasibility and the efficacy of these bioengineered 
exosomes [205]. Despite these encouraging results, before 
moving to the clinic further research is needed, especially to 
reduce the immunogenicity of allogeneic exosomes that are 
enriched in major histocompatibility complex proteins with 
the risk of immune reactions.
8  Clinical Development of MicroRNA‑Based 
Therapeutics
The development of miRNA-targeted therapeutics has 
advanced considerably in recent years, with numerous phase 
I and II trials currently ongoing across a broad range of path-
ologic conditions (Table 1).
8.1  Locked Nucleic Acid‑Antisense Oligonucleotide
As mentioned above, LNA-antisense oligonucleotides are 
used to repress the expression level of endogenous miRNAs 
in the cells. The LNA modification increases the RNAse 
stability of the antisense oligonucleotide and improves 
the binding capacity for complementary sequences. One 
of the earliest and at the same time successful example of 
the translational research efforts behind miRNAs comes 
from the treatment of HCV infection. In a phase IIa trial, a 
15-nucleotide LNA-antisense oligonucleotide complemen-
tary to and with high affinity and specificity for the 5ʹ-region 
of mature miR-122  (Miravirsen®) was administered to 36 
patients with chronic HCV genotype 1 infection [69]. The 
liver-specific miR-122 is (ab-)used by the virus to bind to 
the 5ʹ-untranslated region of the viral genome and thereby 
enhance virus replication [69]. In this study, prolonged 
and dose-dependent reductions in HCV RNA levels were 
observed, including undetectable viral load in five patients, 
with no dose-limiting toxicities [69]. This successful thera-
peutic outcome is based on the fact that no escape muta-
tions in the miR-122-binding sites of the HCV genome were 
found [69]. Miravirsen had a good safety profile with most 
common adverse events such as headache and fatigue that 
were mild in grade and only observed in a few patients [69]. 
Based on these positive results, other studies testing Mira-
virsen either alone or combined with other antiviral agents 
are underway (summarised in Table 1 and [206]). Indeed, 
longer follow-up and larger patient population are needed 
to ensure a proper assessment of both efficacy and safety.
In another first-in-human study based on LNA-modified 
oligonucleotide inhibitor (MRG-106), the onco-miR-155-5p 
was targeted in patients with mycosis fungoides who are in 
clinical stage I–III with plaques or tumours on a stable treat-
ment regimen or without any concomitant therapy [207]. 
During this phase I study, both intratumoral and subcutane-
ous administration of MRG-106 was evaluated and inhibi-
tion of miR-155-5p was well tolerated [207]. In all patients, 
MRG-106-treated lesions had a Composite Assessment of 
Index Lesion Severity score reduction of ≥ 50%, which was 
maintained to the end of the study [207]. One big advantage 
is the significant pharmacodynamic activity of MRG-106 
without requiring additional formulation [207] and by this 
the risk of unwanted side effects is reduced. Furthermore, 
the accessibility of cutaneous lesions provides the oppor-
tunity to apply MRG-106 directly into the tumour area and 
this most probably also reduces off-target effects. Biomarker 
analysis of pre- and post-treatment biopsies showed reduc-
tions in the MAPK/ERK, JAK/STAT and PI3K/AKT sur-
vival pathways in agreement with the expected MRG-106 
mode of action [208]. The simultaneous decreased expres-
sion of several signalling pathways associated with the 
pathogenesis of mycosis fungoides and tumour cell survival 
is of pivotal importance to minimise tumour escape mecha-
nisms. The possibility to target several survival pathways 
in parallel underlines the therapeutic power of LNA-based 
miRNA inhibition. Based on the positive outcome of this 
clinical trial, a phase II study with MRG-106 has recently 
started to recruit patients with cutaneous T-cell lymphoma 
who have confirmed disease progression following treatment 
with vorinostat.
In the setting of a phase I study, the LNA inhibitor MRG-
110 is used to reduce the expression level of the potent anti-
angiogenic miR-92 [209]. MRG-110 is expected to accel-
erate wound healing by improving angiogenesis into the 
wound area when injected into the skin at the site of the 
skin wound. Furthermore, MRG-110 has the advantage of 
reducing off-target effects by applying the inhibitor directly 
into the area of interest. Inhibition of miR-92 increased 
angiogenesis and MRG-110 was safe and generally well 
tolerated when given as 3-weekly intradermal doses. Based 
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on these phase I safety, tolerability, pharmacokinetic, and 
biomarker data, further clinical studies with MRG-110 are 
in preparation to evaluate the ability of this miR-92 inhibi-
tor to enhance vascularisation and function in the setting of 
heart failure.
8.2  MicroRNA Mimic
As mentioned above, miRNA mimics are synthetic oligonu-
cleotide duplexes, which, upon introduction into the cells, 
behave similarly to endogenous miRNAs and they are able 
to restore expression of down-regulated miRNAs. MRX34, 
a liposome-formulated miRNA-34 mimic, has been the first 
miRNA mimic therapeutic to enter a clinical trial in patients 
with solid tumours including hepatocellular carcinoma, renal 
cell carcinoma and melanoma [71]. In a phase I, first-in-
human, dose-escalation study, MRX34 was administered 
intravenously twice weekly for 3 weeks within a 28-day 
cycle (including six total doses of MRX34) in 47 patients 
with heavily pre-treated advanced solid tumours [71]. The 
liposomal miR-34 mimic yielded one prolonged therapeu-
tic effect and a partial response was confirmed by means 
of RECIST criteria in a patient with HCC. Moreover, six 
patients with stable disease were reported, four of whom 
lasted more than four cycles [71]. Despite these encourag-
ing preliminary efficacy and safety data, the trial was put 
on hold by the developing biopharmaceutical company 
itself because of the occurrence of five immune-related 
severe adverse events on a longer study follow-up [210]. It 
is currently unclear whether such adverse events should be 
attributed to the liposome carrier, the double-stranded oli-
gonucleotides, or both, as they are both known to potentially 
trigger pro-inflammatory and immune-mediated side effects 
[210]. Another possible limitation of this approach could be 
the intravenous administration of the miRNA mimic without 
any targeting molecule to increase the specific delivery into 
the tumour.
Following the same approach aimed at restoring the 
expression of down-regulated miRNAs, a miR-16 mimic 
recently entered clinical evaluation in patients with pre-
treated malignant pleural mesothelioma [70]. MesomiR is 
the first compound in a clinical trial to use the ‘TargomIR-
technology’ [161]. TargomiR delivery vesicles are com-
posed of a miRNA mimic and a targeting molecule (e.g. 
a specific antibody that recognises a protein on the target 
cells, in the case of mesomiR, an EGFR antibody is used) 
surrounded by bacterial-derived minicells [211]. In a first-in-
human phase I study, a miR-16 mimic was delivered in Tar-
gomiR vesicles to 26 patients with immunohistochemically 
proven, EGFR-expressing malignant pleural mesothelioma, 
progressing after standard chemotherapy [70]. MesomiRs 
were given over a 20-min intravenous infusion either once 
or twice weekly in a traditional 3 + 3 dose-escalation design 
in five dose cohorts. Among 22 assessable patients, one (5%) 
had a partial response and 15 (68%) had stable disease. The 
administration of MesomiRs was well tolerated and asso-
ciated with early anti-tumour activity. However, toxicity 
concerns emerged as cardiac events were reported in five 
patients [70]. The exact mechanism of the cardiac toxicity 
remains to be understood and, although a carrier-elicited 
inflammatory reaction seems the most plausible explana-
tion, a miRNA mimic-related myocardial injury could not be 
excluded. Pharmacological studies and correlative biomarker 
analyses embedded in future larger clinical trials are war-
ranted to better understand the pharmacokinetic and phar-
macodynamic properties of this new class of therapeutics, 
thus optimising the delivery of next-generation compounds.
In addition, a phase I study based on a miRNA-29b mimic 
(MRG-201) was started recently. By using a miRNA-29b 
mimic, expression of collagen and other proteins involved 
in fibrous scar formation should be reduced. The therapeutic 
substance is injected intradermally [210]. The possibility to 
apply MRG-201 directly into the area of interest will most 
probably reduce off-target effects. According to first results, 
collagen expression and the development of fibroplasia in 
incisional skin wounds have been significantly repressed by 
the application of MRG-201 and a phase II study to treat 
patients with a predisposition for keloid formation with 
MRG-201 is in preparation [212].
8.3  Anti‑MicroRNA
As mentioned before, anti-miRNA are synthetic single-
stranded RNA molecules that, owing to sequence comple-
mentary bind and sequester endogenous miRNAs and by 
this counteract up-regulated miRNAs. MiR-10b is higher 
expressed in glioblastoma compared with normal brain tis-
sue [213] and therefore the critical function of anti-mir-10b 
(EXTH-61) in blocking established glioblastoma growth is 
under investigation in a phase I study [214]. Owing to the 
fact that miRNAs are able to cross the blood–brain barrier, 
EXTH-61 could be a further option to overcome the difficul-
ties in treating glioblastoma. However, there is the question 
on how specific EXTH-61 is taken up by glioblastoma and it 
will be of interest to see if the anti-miR-10b construct causes 
off-target effects.
In another phase I/IIa clinical study, 46 patients with 
type 2 diabetes mellitus and non-alcoholic fatty liver dis-
ease receiving metformin monotherapy will be included. 
A role of miR-103/107 in insulin sensitivity and resistance 
has been established [215] and, in this study, inhibition of 
this miRNA via N-acetylgalactosamine conjugated anti-
miR-103/107 (RG-125) will be explored. This study was 
stopped by the company before results were made available.
Following the same approach, anti-miR-122 was used 
as a conjugate with N-acetylgalactosamine (RG-101) in a 
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multicentre phase Ib study to treat HCV-infected patients 
who were either treatment naïve or relapsed after interferon-
α-based therapy [216, 217]. Twenty-eight patients received 
one subcutaneous injection of RG-101 and after 4 weeks the 
viral load was significantly reduced in all patients and the 
substance was well tolerated. Three patients had undetect-
able HCV RNA levels even 76 weeks after a single dose of 
RG-101. In some cases, the observed viral rebound after 
12 weeks was associated with the appearance of resist-
ance mediating mutations in miR-122-binding regions in 
the 5′-untranslated region of the HCV genome [217]. Nev-
ertheless, because of high levels of bilirubin in the blood 
of the patients, the company decided to terminate the tri-
als based on RG-101. Off-target effects of RG-101 are 
the inhibition of conjugated bilirubin transport, impaired 
baseline bilirubin transport and the preferential uptake of 
RG-101 by hepatocytes resulting in hyperbilirubinemia. 
This study targets miR-122 in HCV-infected patients like 
for Miravirsen (described in Sect. 8.1). Locked nucleic 
acid-antisense-based therapy has an advantage and results 
in fewer side effects compared with the anti-miRNA strat-
egy. Furthermore, no escape mutations have been observed 
in patients treated with Miravirsen, but surprisingly, such 
escape mutations occur during treatment with anti-miR-122 
even if both strategies target endogenous miR-122. Consid-
ering that both RG-125 as well as RG-101 studies are based 
on a N-acetylgalactosamine conjugated anti-miRNA, and 
both have been suspended, it is tempting to speculate that 
N-acetylgalactosamine conjugation is at least in some part 
involved in unwanted side effects.
Finally, anti-miR-21 (RG-012) was tested in a phase I 
study for the efficiency to treat fibrogenetic diseases espe-
cially Alport nephropathy [218]. Alport syndrome is a life-
threating hereditary kidney disease that currently has no 
approved therapy [219]. An anti-miRNA-based strategy 
could be a therapeutic option for rare and orphan diseases 
such as Alport syndrome for which no drugs for treatment 
have been developed owing to the small number of patients. 
One issue of this study is the very limited information on 
exactly how Alport syndrome progresses, although miR-21 
is believed to play a central role in the disease progression. 
Furthermore, RG-012 is missing a targeting molecule to 
increase the specific delivery into the kidney and therefore 
off-target effects are very likely.
9  Clinical Development of Long Non‑Coding 
RNA‑Based Therapeutics
No clinical trials targeting lncRNAs have been started. Nev-
ertheless, the first pre-clinical studies are underway and the 
first patent for using lncRNA as a therapeutic target has been 
issued (patent CA 2921457). In several pre-clinical studies, 
the potential benefit of lncRNA-based therapies for cancer 
have been demonstrated. Tumour growth and reduction in 
metastatic sites have been strongly affected by knocking-
down lncRNA MALAT1 by a specific ASO in models for 
breast and lung cancer [179, 220]. Antisense oligonucleo-
tide-mediated down-regulation of lncRN ASChLAP1 has 
been found to limit tumour formation and metastasis of pros-
tate cancer [221]. Another study using ASO directed against 
lncRNA USMycN significantly reduced tumour formation 
in mice with neuroblastoma [222]. The lncRNA-GMAN is 
highly expressed in gastric cancer cells and is associated 
with metastatic processes and poor prognosis. By using a 
CRISPR/Cas9 system targeting lncRNA-GMAN, metastasis 
of gastric cancer cells was significant reduced and overall 
survival was improved in a mice model [223].
Furthermore, lncRNAs can also influence the sensitivity 
of cancer cells towards different types of drugs. Silencing 
the expression of lncRNA-NEAT1 increased the sensitivity 
of pre-cancerous cells towards DNA damage-induced cell 
death and increased lethality of chemotherapy drugs on can-
cer cells [224]. All these examples underline the significant 
role of dysregulated lncRNAs in the context of cancer and 
demonstrate the potential therapeutic power that could result 
from modifying lncRNA expression.
Of special interest are some clinical phase I/II trials 
(Table 2) in which the anti-tumour efficiency of a plasmid 
coding for the A subunit of diphtheria toxin under the control 
Table 2  Clinical trials using long non-coding RNA promoter for specific expression of therapeutics in tumour cells
NMIBC non-muscle invasive bladder cancer
Drug name Disease Phase Status ClinicalTrials.
gov identifier
BC-819 Unresponsive NMIBC II Recruting NCT03719300
BC-819 Locally advanced pancreatic adenocarcinoma IIb Terminated NCT01413087
BC-819 Superficial transitional cell bladder carcinoma I Completed NCT01878188
BC-819 Advanced ovarian cancer I/IIa Completed NCT00826150
BC-819 Unresectable pancreatic cancer II Completed NCT00711997
BC-819 Intermediate-risk superficial bladder cancer II Completed NCT00595088
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of the lncRNA H19 gene promoter (BC-819) is evaluated 
in different solid tumours [225–231]. Based on the highly 
selective tissue expression of lncRNAs such as H19, 22% 
of the patients with cancer have a complete response and 
44% have a partial response [229]. Furthermore, observed 
side effects are minimal and BC-819 can be considered as 
safe and well tolerated, thus clinical phase III trials are in 
preparation [228].
10  Conclusions
The interest in non-coding RNA-based therapeutics was 
boosted by the first Food and Drug Administration approval 
of a small-interfering RNA drug in 2018. This small-inter-
fering RNA drug called patisiran targets and degrades the 
mRNA coding for transthyretin and is used to treat polyneu-
ropathy caused by hereditary transthyretin-mediated amyloi-
dosis [232, 233].
Nevertheless, increasing knowledge about non-coding 
RNAs especially about lncRNAs is a prerequisite for using 
the non-coding RNAs as therapeutic targets. Notably, intra- 
and inter-tumoral heterogeneity are pitfalls in the study of 
non-coding RNA targets given the tissue-specific interac-
tion. Long non-coding RNAs as well as miRNA expression 
indeed can vary from one area to another in the same tissue 
as well as over time; moreover, numerous concomitant con-
ditions can alter the expression levels of non-coding RNAs 
[234, 235]. Clearly, non-coding RNA-based therapy is still 
in its infancy. It is very attractive to use these new targets as 
a further therapeutic option in the context of different dis-
eases because non-coding RNAs are often expressed in a tis-
sue- and cell type-specific manner and their deregulation is 
disease specific. However, it is also necessary to improve the 
methods for tissue- and cell type-specific delivery and the 
targeting of deregulated non-coding RNAs as well as reduc-
ing off-target effects especially innate immune responses.
The therapeutic manipulation of miRNAs has gained 
momentum based on their causative involvement in a broad 
range of human diseases, ranging from infections to can-
cer. MicroRNA-targeted therapeutics have recently entered 
clinical evaluations showing encouraging safety and effi-
cacy in early-phase trials, particularly in patients with HCV 
infection and malignant pleural mesothelioma [161, 236]. 
Furthermore, non-coding RNA-based therapies represent 
an option for life-threatening disease that currently has no 
approved therapy [219]. A suboptimal in-vivo delivery and 
emerging side effects could represent drawbacks in suc-
cessfully translating these compounds to the clinic. A better 
understanding of their pharmacological properties alongside 
safer and more efficient delivery technologies will hopefully 
help realise the tremendous potential of non-coding RNA-
based therapeutics.
Authors’ Contributions MR, NV and JCH conceived and designed the 
study. MR, AL, MBM and JCH wrote the paper; AL designed the 
figures; MG and MS summarised the data, analysed the data and cre-
ated the tables; NV and JCH reviewed and edited the manuscript. All 
authors read, critically reviewed and approved the final manuscript.
Compliance with Ethical Standards 
Funding No external funding was used in the preparation of this arti-
cle.
Conflict of Interest Margherita Ratti, Andrea Lampis, Michele Ghi-
dini, Massimiliano Salati, Milko B. Mirchev and Jens C. Hahne have 
no conflicts of interest that are directly relevant to the content of this 
article. Nicola Valeri received speaker honorarium from Bayer, Eli-
Lilly, Pfizer and Merck.
Open Access This article is licensed under a Creative Commons Attri-
bution-NonCommercial 4.0 International License, which permits any 
non-commercial use, sharing, adaptation, distribution and reproduction 
in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Com-
mons licence, and indicate if changes were made. The images or other 
third party material in this article are included in the article’s Creative 
Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons 
licence and your intended use is not permitted by statutory regula-
tion or exceeds the permitted use, you will need to obtain permission 
directly from the copyright holder.To view a copy of this licence, visit 
http://creat iveco mmons .org/licen ses/by-nc/4.0/.
References
 1. Dozmorov MG, Giles CB, Koelsch KA, Wren JD. Systematic 
classification of non-coding RNAs by epigenomic similarity. 
BMC Bioinform. 2013;14(Suppl. 14):S2.
 2. An Y, Furber KL, Ji S. Pseudogenes regulate paren-
tal gene expression via ceRNA network. J Cell Mol Med. 
2017;21(1):185–92.
 3. Azlan A, Dzaki N, Azzam G. Argonaute: the executor of small 
RNA function. J Genet Genom. 2016;43(8):481–94.
 4. Choudhuri S. Small noncoding RNAs: biogenesis, function, and 
emerging significance in toxicology. J Biochem Mol Toxicol. 
2010;24(3):195–21616.
 5. Claycomb JM. Ancient endo-siRNA pathways reveal new tricks. 
Curr Biol. 2014;24(15):R703–R715.
 6. de Almeida RA, Fraczek MG, Parker S, Delneri D, O’Keefe RT. 
Non-coding RNAs and disease: the classical ncRNAs make a 
comeback. Biochem Soc Trans. 2016;44(4):1073–8.
 7. Eddy SR. Non-coding RNA genes and the modern RNA world. 
Nat Rev Genet. 2001;2(12):919–29.
 8. Evans JR, Feng FY, Chinnaiyan AM. The bright side of dark 
matter: lncRNAs in cancer. J Clin Invest. 2016;126(8):2775–822.
 9. Geiger J, Dalgaard LT. Interplay of mitochondrial metabolism 
and microRNAs. Cell Mol Life Sci. 2017;74(4):631–46.
 10. Granados-Riveron JT, Aquino-Jarquin G. The complexity of 
the translation ability of circRNAs. Biochim Biophys Acta. 
2016;1859(10):1245–51.
 11. Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identifica-
tion and characterization of mammalian circular RNAs. Genome 
Biol. 2014;15(7):409.
Non-Coding RNA-Based Therapeutics
 12. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser 
D, et al. Chromatin signature reveals over a thousand highly 
conserved large non-coding RNAs in mammals. Nature. 
2009;458(7235):223–7.
 13. Hahne JC, Valeri N. Non-coding RNAs and resistance to antican-
cer drugs in gastrointestinal tumors. Front Oncol. 2018;8:226.
 14. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in 
gene regulation. Nat Rev Genet. 2004;5(7):522–31.
 15. Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA, Ger-
stein M. Role of non-coding sequence variants in cancer. Nat Rev 
Genet. 2016;17(2):93–108.
 16. Langenberger D, Bermudez-Santana C, Hertel J, Hoffmann 
S, Khaitovich P, Stadler PF. Evidence for human microRNA-
offset RNAs in small RNA sequencing data. Bioinformatics. 
2009;25(18):2298–301.
 17. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding 
RNAs as targets for anticancer drug development. Nat Rev Drug 
Discov. 2013;12(11):847–65.
 18. Qi P, Zhou XY, Du X. Circulating long non-coding RNAs in 
cancer: current status and future perspectives. Mol Cancer. 
2016;15(1):39.
 19. Taft RJ, Glazov EA, Cloonan N, Simons C, Stephen S, Faulkner 
GJ, et al. Tiny RNAs associated with transcription start sites in 
animals. Nat Genet. 2009;41(5):572–8.
 20. Taft RJ, Glazov EA, Lassmann T, Hayashizaki Y, Carninci 
P, Mattick JS. Small RNAs derived from snoRNAs. RNA. 
2009;15(7):1233–40.
 21. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: 
functional surprises from the RNA world. Genes Dev. 
2009;23(13):1494–504.
 22. Quinn JJ, Chang HY. Unique features of long non-coding RNA 
biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.
 23. Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs 
in development and disease: background, mechanisms, and thera-
peutic approaches. Physiol Rev. 2016;96(4):1297–325.
 24. Geisler S, Coller J. RNA in unexpected places: long non-coding 
RNA functions in diverse cellular contexts. Nat Rev Mol Cell 
Biol. 2013;14(11):699–712.
 25. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 
2006;15(1):17–29.
 26. Morris KV, Mattick JS. The rise of regulatory RNA. Nat Rev 
Genet. 2014;15(6):423–37.
 27. Kim SS, Lee SV. Non-coding RNAs in Caenorhabditis elegans 
aging. Mol Cells. 2019;42(5):379–85.
 28. Boehm M, Slack F. A developmental timing microRNA 
and its target regulate life span in C. elegans. Science. 
2005;310(5756):1954–7.
 29. Fernandes JCR, Acuna SM, Aoki JI, Floeter-Winter LM, Muxel 
SM. Long non-coding RNAs in the regulation of gene expres-
sion: physiology and disease. Noncoding RNA. 2019;5(1):17.
 30. Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in 
cancer. Int J Mol Sci. 2018;19(5):1310.
 31. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and 
function. Cell. 2004;116(2):281–97.
 32. Hwang HW, Wentzel EA, Mendell JT. A hexanucleo-
tide element directs microRNA nuclear import. Science. 
2007;315(5808):97–100.
 33. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 
5’UTR of ribosomal protein mRNAs and enhances their transla-
tion. Mol Cell. 2008;30(4):460–71.
 34. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat 
F, et al. Modulation of mismatch repair and genomic stability by 
miR-155. Proc Natl Acad Sci USA. 2010;107(15):6982–7.
 35. Vasudevan S, Tong Y, Steitz JA. Switching from repression to 
activation: microRNAs can up-regulate translation. Science. 
2007;318(5858):1931–4.
 36. Saito T, Saetrom P. MicroRNAs: targeting and target prediction. 
N Biotechnol. 2010;27(3):243–9.
 37. Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function 
and role in cancer. Curr Genom. 2010;11(7):537–61.
 38. Pasquinelli AE. MicroRNAs and their targets: recognition, regu-
lation and an emerging reciprocal relationship. Nat Rev Genet. 
2012;13(4):271–82.
 39. Li Z, Yang CS, Nakashima K, Rana TM. Small RNA-mediated 
regulation of iPS cell generation. EMBO J. 2011;30(5):823–34.
 40. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 
targets a network of key tumor-suppressive pathways in glio-
blastoma cells. Cancer Res. 2008;68(19):8164–72.
 41. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel 
W, Tuschl T. Identification of tissue-specific microRNAs from 
mouse. Curr Biol. 2002;12(9):735–9.
 42. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, 
Castle J, et al. Microarray analysis shows that some microR-
NAs downregulate large numbers of target mRNAs. Nature. 
2005;433(7027):769–73.
 43. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and 
cancer: a brief overview. Adv Biol Regul. 2015;57:1–9.
 44. Balatti V, Pekarky Y, Croce CM. Role of microRNA in chronic 
lymphocytic leukemia onset and progression. J Hematol Oncol. 
2015;8:12.
 45. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 
2011;12(12):861–74.
 46. Ghidini M, Hahne JC, Frizziero M, Tomasello G, Trevisani F, 
Lampis A, et al. MicroRNAs as mediators of resistance mecha-
nisms to small-molecule tyrosine kinase inhibitors in solid 
tumours. Target Oncol. 2018;13(4):423–36.
 47. O’Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physi-
ological and pathological roles for microRNAs in the immune 
system. Nat Rev Immunol. 2010;10(2):111–22.
 48. Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, 
et al. miRNAS in cardiovascular diseases: potential biomark-
ers, therapeutic targets and challenges. Acta Pharmacol Sin. 
2018;39(7):1073–84.
 49. Garibaldi F, Falcone E, Trisciuoglio D, Colombo T, Lisek K, 
Walerych D, et  al. Mutant p53 inhibits miRNA biogenesis 
by interfering with the microprocessor complex. Oncogene. 
2016;35(29):3760–70.
 50. Gurtner A, Falcone E, Garibaldi F, Piaggio G. Dysregulation of 
microRNA biogenesis in cancer: the impact of mutant p53 on 
Drosha complex activity. J Exp Clin Cancer Res. 2016;35:45.
 51. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. 
Nat Rev Cancer. 2015;15(6):321–33.
 52. Croce CM. Causes and consequences of microRNA dysregula-
tion in cancer. Nat Rev Genet. 2009;10(10):704–14.
 53. Hahne JC, Mirchev M, Kotzev I, Lampis A, Valeri N. Biomarkers 
for monitoring response to therapies and detection of acquired 
resistance in advanced gastrointestinal cancers. Front Clin Drug 
Res. 2017;4:1–73.
 54. Anandappa G, Lampis A, Cunningham D, Khan KH, Kouvela-
kis K, Vlachogiannis G, et al. miR-31-3p expression and ben-
efit from anti-EGFR inhibitors in metastatic colorectal cancer 
patients enrolled in the prospective phase II PROSPECT-C trial. 
Clin Cancer Res. 2019;25(13):3830–8.
 55. Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat 
S, Burke R, et al. MIR21 drives resistance to heat shock pro-
tein 90 inhibition in cholangiocarcinoma. Gastroenterology. 
2018;154(4):1066–79.e5.
 56. Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghi-
dini M, et al. Sequence variation in mature microRNA-608 and 
benefit from neo-adjuvant treatment in locally advanced rectal 
cancer patients. Carcinogenesis. 2016;37(9):852–7.
 M. Ratti et al.
 57. Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragu-
lan C, Tan IB, et al. A seven-gene signature assay improves prog-
nostic risk stratification of perioperative chemotherapy treated 
gastroesophageal cancer patients from the MAGIC trial. Ann 
Oncol. 2018;29(12):2356–62.
 58. Trevisani F, Ghidini M, Larcher A, Lampis A, Lote H, Manunta 
P, et al. MicroRNA 193b–3p as a predictive biomarker of chronic 
kidney disease in patients undergoing radical nephrectomy for 
renal cell carcinoma. Br J Cancer. 2016;115(11):1343–50.
 59. Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee SS. Ther-
apeutic miRNA and siRNA: moving from bench to clinic as next 
generation medicine. Mol Ther Nucleic Acids. 2017;8:132–43.
 60. Abba ML, Patil N, Leupold JH, Moniuszko M, Utikal J, Niklinski 
J, et al. MicroRNAs as novel targets and tools in cancer therapy. 
Cancer Lett. 2017;387:84–94.
 61. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new 
era for the management of cancer and other diseases. Nat Rev 
Drug Discov. 2017;16(3):203–22.
 62. Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH. MicroRNA 
manipulation in colorectal cancer cells: from laboratory to clini-
cal application. J Transl Med. 2012;10:128.
 63. van Rooij E, Marshall WS, Olson EN. Toward microRNA-based 
therapeutics for heart disease: the sense in antisense. Circ Res. 
2008;103(9):919–28.
 64. Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. 
MicroRNA therapeutics: discovering novel targets and develop-
ing specific therapy. Perspect Clin Res. 2016;7(2):68–74.
 65. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often 
flanked by adenosines, indicates that thousands of human genes 
are microRNA targets. Cell. 2005;120(1):15–20.
 66. Bader AG, Brown D, Winkler M. The promise of microRNA 
replacement therapy. Cancer Res. 2010;70(18):7027–30.
 67. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic 
gene lin-4 encodes small RNAs with antisense complementarity 
to lin-14. Cell. 1993;75(5):843–54.
 68. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of 
the heterochronic gene lin-14 by lin-4 mediates temporal pattern 
formation in C. elegans. Cell. 1993;75(5):855–62.
 69. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Tor-
res M, Patel K, et al. Treatment of HCV infection by targeting 
microRNA. N Engl J Med. 2013;368(18):1685–94.
 70. van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, 
Clarke S, et al. Safety and activity of microRNA-loaded mini-
cells in patients with recurrent malignant pleural mesothelioma: 
a first-in-man, phase 1, open-label, dose-escalation study. Lancet 
Oncol. 2017;18(10):1386–96.
 71. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stou-
demire J, et al. Phase I study of MRX34, a liposomal miR-34a 
mimic, administered twice weekly in patients with advanced 
solid tumors. Invest New Drugs. 2017;35(2):180–8.
 72. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam 
R, et al. MicroRNAs bind to Toll-like receptors to induce pro-
metastatic inflammatory response. Proc Natl Acad Sci USA. 
2012;109(31):E2110–E2116.
 73. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, 
Pogosova-Agadjanyan EL, et al. Circulating microRNAs as sta-
ble blood-based markers for cancer detection. Proc Natl Acad Sci 
USA. 2008;105(30):10513–8.
 74. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya 
T. Secretory mechanisms and intercellular transfer of microR-
NAs in living cells. J Biol Chem. 2010;285(23):17442–52.
 75. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall 
JO. Exosome-mediated transfer of mRNAs and microRNAs is 
a novel mechanism of genetic exchange between cells. Nat Cell 
Biol. 2007;9(6):654–9.
 76. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson 
DF, et al. Argonaute2 complexes carry a population of circulat-
ing microRNAs independent of vesicles in human plasma. Proc 
Natl Acad Sci USA. 2011;108(12):5003–8.
 77. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, 
Remaley AT. MicroRNAs are transported in plasma and deliv-
ered to recipient cells by high-density lipoproteins. Nat Cell 
Biol. 2011;13(4):423–33.
 78. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of 
microRNAs and microRNA-protective protein by mammalian 
cells. Nucleic Acids Res. 2010;38(20):7248–59.
 79. Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted micro-
RNAs: a new form of intercellular communication. Trends Cell 
Biol. 2012;22(3):125–32.
 80. Haimovich G, Ecker CM, Dunagin MC, Eggan E, Raj A, Gerst 
JE, et al. Intercellular mRNA trafficking via membrane nano-
tube-like extensions in mammalian cells. Proc Natl Acad Sci 
USA. 2017;114(46):E9873–E9882.
 81. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, 
Munson G, et al. lincRNAs act in the circuitry controlling pluri-
potency and differentiation. Nature. 2011;477(7364):295–300.
 82. Herriges MJ, Swarr DT, Morley MP, Rathi KS, Peng T, Stewart 
KM, et al. Long noncoding RNAs are spatially correlated with 
transcription factors and regulate lung development. Genes 
Dev. 2014;28(12):1363–79.
 83. Li G, Zhang H, Wan X, Yang X, Zhu C, Wang A, et al. Long 
noncoding RNA plays a key role in metastasis and prognosis of 
hepatocellular carcinoma. Biomed Res Int. 2014;2014:780521.
 84. Ounzain S, Pezzuto I, Micheletti R, Burdet F, Sheta R, Nemir 
M, et al. Functional importance of cardiac enhancer-associated 
noncoding RNAs in heart development and disease. J Mol Cell 
Cardiol. 2014;76:55–70.
 85. Sauvageau M, Goff LA, Lodato S, Bonev B, Groff AF, Ger-
hardinger C, et al. Multiple knockout mouse models reveal 
lincRNAs are required for life and brain development. Elife. 
2013;2:e01749.
 86. Wu Z, Liu X, Liu L, Deng H, Zhang J, Xu Q, et al. Regulation 
of lncRNA expression. Cell Mol Biol Lett. 2014;19(4):561–75.
 87. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean 
S, et al. microRNA-29 can regulate expression of the long non-
coding RNA gene MEG3 in hepatocellular cancer. Oncogene. 
2011;30(47):4750–6.
 88. Noh JH, Kim KM, McClusky WG, Abdelmohsen K, Gorospe 
M. Cytoplasmic functions of long noncoding RNAs. Wiley 
Interdiscp Rev RNA. 2018;9(3):e1471.
 89. Sun QY, Hao QY, Prasanth KV. Nuclear long noncoding 
RNAs: key regulators of gene expression. Trends Genet. 
2018;34(2):142–57.
 90. Ribeiro DM, Zanzoni A, Cipriano A, Delli Ponti R, Spinelli L, 
Ballarino M, et al. Protein complex scaffolding predicted as a 
prevalent function of long non-coding RNAs. Nucleic Acids 
Res. 2018;46(2):917–28.
 91. Han P, Chang CP. Long non-coding RNA and chromatin 
remodeling. RNA Biol. 2015;12(10):1094–8.
 92. Kornienko AE, Guenzl PM, Barlow DP, Pauler FM. Gene regu-
lation by the act of long non-coding RNA transcription. BMC 
Biol. 2013;11:59.
 93. Moran VA, Perera RJ, Khalil AM. Emerging functional and 
mechanistic paradigms of mammalian long non-coding RNAs. 
Nucleic Acids Res. 2012;40(14):6391–400.
 94. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu 
X, et al. Long noncoding RNA MALAT1 controls cell cycle 
progression by regulating the expression of oncogenic tran-
scription factor B-MYB. PLoS Genet. 2013;9(3):e1003368.
Non-Coding RNA-Based Therapeutics
 95. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, 
et al. Activation of p53 by MEG3 non-coding RNA. J Biol 
Chem. 2007;282(34):24731–42.
 96. Matouk I, Raveh E, Ohana P, Abu Lail R, Gershtain E, Gilon 
M, et al. The increasing complexity of the oncofetal H19 gene 
locus: functional dissection and therapeutic intervention. Int J 
Mol Sci. 2013;14(2):4298–316.
 97. Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, Petrovics 
G, et al. A long noncoding RNA connects c-Myc to tumor metab-
olism. Proc Natl Acad Sci U S A. 2014;111(52):18697–702.
 98. Marin-Bejar O, Marchese FP, Athie A, Sanchez Y, Gonzalez J, 
Segura V, et al. Pint lincRNA connects the p53 pathway with epi-
genetic silencing by the Polycomb repressive complex 2. Genome 
Biol. 2013;14(9):R104.
 99. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzel-
mann-Broz D, et al. A large intergenic noncoding RNA induced 
by p53 mediates global gene repression in the p53 response. Cell. 
2010;142(3):409–19.
 100. Sanchez Y, Segura V, Marin-Bejar O, Athie A, Marchese FP, 
Gonzalez J, et al. Genome-wide analysis of the human p53 tran-
scriptional network unveils a lncRNA tumour suppressor signa-
ture. Nat Commun. 2014;5:5812.
 101. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-lail R, Fellig 
Y, et al. The oncofetal H19 RNA connection: hypoxia, p53 and 
cancer. Biochim Biophys Acta. 2010;1803(4):443–51.
 102. Yoon JH, Abdelmohsen K, Gorospe M. Functional interactions 
among microRNAs and long noncoding RNAs. Semin Cell Dev 
Biol. 2014;34:9–14.
 103. Lopez-Urrutia E, Bustamante Montes LP, Ladron de Guevara 
Cervantes D, Perez-Plasencia C, Campos-Parra AD. Crosstalk 
between long non-coding RNAs, micro-RNAs and mRNAs: deci-
phering molecular mechanisms of master regulators in cancer. 
Front Oncol. 2019;9:669.
 104. Arun G, Diermeier SD, Spector DL. Therapeutic target-
ing of long non-coding RNAs in cancer. Trends Mol Med. 
2018;24(3):257–77.
 105. Hobuss L, Bar C, Thum T. Long non-coding RNAs: at the heart 
of cardiac dysfunction? Front Physiol. 2019;10:30.
 106. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev 
A, et al. Integrative annotation of human large intergenic non-
coding RNAs reveals global properties and specific subclasses. 
Genes Dev. 2011;25(18):1915–27.
 107. Fatica A, Bozzoni I. Long non-coding RNAs: new play-
ers in cell differentiation and development. Nat Rev Genet. 
2014;15(1):7–21.
 108. Martignano F, Rossi L, Maugeri A, Galla V, Conteduca V, De 
Giorgi U, et al. Urinary RNA-based biomarkers for prostate can-
cer detection. Clin Chim Acta. 2017;473:96–105.
 109. Terracciano D, Ferro M, Terreri S, Lucarelli G, D’Elia C, Musi 
G, et al. Urinary long noncoding RNAs in nonmuscle-invasive 
bladder cancer: new architects in cancer prognostic biomarkers. 
Transl Res. 2017;184:108–17.
 110. Zhou XY, Yin CQ, Dang YN, Ye F, Zhang GX. Identification of 
the long non-coding RNA H19 in plasma as a novel biomarker 
for diagnosis of gastric cancer. Sci Rep. 2015;5.
 111. Li Q, Shao YF, Zhang XJ, Zheng T, Miao M, Qin LJ, et al. 
Plasma long noncoding RNA protected by exosomes as a 
potential stable biomarker for gastric cancer. Tumor Biol. 
2015;36(3):2007–122.
 112. Viereck J, Thum T. Circulating noncoding RNAs as bio-
markers of cardiovascular disease and injury. Circ Res. 
2017;120(2):381–99.
 113. Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, 
Holzmann A, et  al. Circulating long noncoding RNA, LIP-
CAR, predicts survival in patients with heart failure. Circ Res. 
2014;114(10):1569–75.
 114. Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of 
lncRNA in cancer and therapeutic opportunities. Am J Cancer 
Res. 2019;9(7):1354–66.
 115. Betts JA, Moradi Marjaneh M, Al-Ejeh F, Lim YC, Shi W, Siva-
kumaran H, et al. Long noncoding RNAs CUPID1 and CUPID2 
mediate breast cancer risk at 11q13 by modulating the response 
to DNA damage. Am J Hum Genet. 2017;101(2):255–66.
 116. Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, et al. The LINK-
A lncRNA activates normoxic HIF1alpha signalling in triple-
negative breast cancer. Nat Cell Biol. 2016;18(2):213–24.
 117. Shih JW, Chiang WF, Wu ATH, Wu MH, Wang LY, Yu YL, 
et al. Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-
1alpha co-activator driving oral cancer progression. Nat Com-
mun. 2017;8:15874.
 118. Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F, et al. 
Repression of the long noncoding RNA-LET by histone dea-
cetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell. 
2013;49(6):1083–96.
 119. Xiao ZD, Han L, Lee H, Zhuang L, Zhang Y, Baddour J, et al. 
Energy stress-induced lncRNA FILNC1 represses c-Myc-medi-
ated energy metabolism and inhibits renal tumor development. 
Nat Commun. 2017;8(1):783.
 120. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long 
noncoding RNA activated by TGF-beta promotes the invasion-
metastasis cascade in hepatocellular carcinoma. Cancer Cell. 
2014;25(5):666–81.
 121. Huang JF, Guo YJ, Zhao CX, Yuan SX, Wang Y, Tang GN, et al. 
Hepatitis B virus X protein (HBx)-related long noncoding RNA 
(lncRNA) down-regulated expression by HBx (Dreh) inhibits 
hepatocellular carcinoma metastasis by targeting the intermediate 
filament protein vimentin. Hepatology. 2013;57(5):1882–92.
 122. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong 
DJ, et  al. Long non-coding RNA HOTAIR reprograms 
chromatin state to promote cancer metastasis. Nature. 
2010;464(7291):1071–6.
 123. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt 
R, et al. HOTAIR is a negative prognostic factor and exhib-
its pro-oncogenic activity in pancreatic cancer. Oncogene. 
2013;32(13):1616–25.
 124. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, et al. Over-
expression of long non-coding RNA HOTAIR predicts tumor 
recurrence in hepatocellular carcinoma patients following liver 
transplantation. Ann Surg Oncol. 2011;18(5):1243–50.
 125. Ren Y, Jia HH, Xu YQ, Zhou X, Zhao XH, Wang YF, et al. 
Paracrine and epigenetic control of CAF-induced metastasis: the 
role of HOTAIR stimulated by TGF-ss1 secretion. Mol Cancer. 
2018;17(1):5.
 126. Heward JA, Lindsay MA. Long non-coding RNAs in the 
regulation of the immune response. Trends Immunol. 
2014;35(9):408–19.
 127. Atianand MK, Hu W, Satpathy AT, Shen Y, Ricci EP, Alvarez-
Dominguez JR, et al. A long noncoding RNA lincRNA-EPS 
acts as a transcriptional brake to restrain inflammation. Cell. 
2016;165(7):1672–85.
 128. Wang P, Xue Y, Han Y, Lin L, Wu C, Xu S, et al. The STAT3-
binding long noncoding RNA lnc-DC controls human dendritic 
cell differentiation. Science. 2014;344(6181):310–3.
 129. Ranzani V, Rossetti G, Panzeri I, Arrigoni A, Bonnal RJ, Curti 
S, et al. The long intergenic noncoding RNA landscape of human 
lymphocytes highlights the regulation of T cell differentiation by 
linc-MAF-4. Nat Immunol. 2015;16(3):318–25.
 130. Hu G, Tang Q, Sharma S, Yu F, Escobar TM, Muljo SA, et al. 
Expression and regulation of intergenic long noncoding RNAs 
during T cell development and differentiation. Nat Immunol. 
2013;14(11):1190–8.
 M. Ratti et al.
 131. Jiang R, Tang J, Chen Y, Deng L, Ji J, Xie Y, et al. The long non-
coding RNA lnc-EGFR stimulates T-regulatory cells differentia-
tion thus promoting hepatocellular carcinoma immune evasion. 
Nat Commun. 2017;8:15129.
 132. Chen C, He W, Huang J, Wang B, Li H, Cai Q, et  al. 
LNMAT1 promotes lymphatic metastasis of bladder cancer 
via CCL2 dependent macrophage recruitment. Nat Commun. 
2018;9(1):3826.
 133. Huang D, Chen J, Yang L, Ouyang Q, Li J, Lao L, et  al. 
NKILA lncRNA promotes tumor immune evasion by sensi-
tizing T cells to activation-induced cell death. Nat Immunol. 
2018;19(10):1112–25.
 134. Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, 
Buzas EI, et al. Biological properties of extracellular vesi-
cles and their physiological functions. J Extracell Vesicles. 
2015;4:27066.
 135. Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA. The fusion 
of two worlds: non-coding RNAs and extracellular vesicles: 
diagnostic and therapeutic implications (review). Int J Oncol. 
2015;46(1):17–27.
 136. Nana-Sinkam SP, Croce CM. MicroRNA regulation of tumo-
rigenesis, cancer progression and interpatient heterogeneity: 
towards clinical use. Genome Biol. 2014;15(9):445.
 137. Sanchez Y, Huarte M. Long non-coding RNAs: challenges for 
diagnosis and therapies. Nucleic Acid Ther. 2013;23(1):15–20.
 138. Costa MC, Kurc S, Drozdz A, Cortez-Dias N, Enguita FJ. The 
circulating non-coding RNA landscape for biomarker research: 
lessons and prospects from cardiovascular diseases. Acta Phar-
macol Sin. 2018;39(7):1085–99.
 139. Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating micro-
RNA-1 as a potential novel biomarker for acute myocardial 
infarction. Biochem Biophys Res Commun. 2010;391(1):73–7.
 140. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circu-
lating microRNA: a novel potential biomarker for early diag-
nosis of acute myocardial infarction in humans. Eur Heart J. 
2010;31(6):659–66.
 141. Bye A, Rosjo H, Nauman J, Silva GJ, Follestad T, Omland T, 
et al. Circulating microRNAs predict future fatal myocardial 
infarction in healthy individuals: the HUNT study. J Mol Cell 
Cardiol. 2016;97:162–8.
 142. Zhang Y, Sun L, Xuan L, Pan Z, Li K, Liu S, et al. Recipro-
cal changes of circulating long non-coding RNAs ZFAS1 
and CDR1AS predict acute myocardial infarction. Sci Rep. 
2016;6:22384.
 143. Koh W, Pan W, Gawad C, Fan HC, Kerchner GA, Wyss-Coray 
T, et  al. Noninvasive in  vivo monitoring of tissue-specific 
global gene expression in humans. Proc Natl Acad Sci USA. 
2014;111(20):7361–6.
 144. Liu Z, Li X, Sun N, Xu Y, Meng Y, Yang C, et al. Microar-
ray profiling and co-expression network analysis of circulating 
lncRNAs and mRNAs associated with major depressive disorder. 
PLoS ONE. 2014;9(3):e93388.
 145. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dun-
ning MJ, et al. MicroRNA expression profiling of human breast 
cancer identifies new markers of tumor subtype. Genome Biol. 
2007;8(10):R214.
 146. Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky 
I, Edmonston TB, et al. Classification of the four main types of 
lung cancer using a microRNA-based diagnostic assay. J Mol 
Diagn. 2012;14(5):510–7.
 147. Pentheroudakis G, Pavlidis N, Fountzilas G, Krikelis D, Gous-
sia A, Stoyianni A, et al. Novel microRNA-based assay demon-
strates 92% agreement with diagnosis based on clinicopathologic 
and management data in a cohort of patients with carcinoma of 
unknown primary. Mol Cancer. 2013;12:57.
 148. Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafa R, Magri E, 
et al. MicroRNA profiling for the identification of cancers with 
unknown primary tissue-of-origin. J Pathol. 2011;225(1):43–53.
 149. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, 
et al. APTIMA PCA3 molecular urine test: development of a 
method to aid in the diagnosis of prostate cancer. Clin Chem. 
2006;52(6):1089–95.
 150. Pal RP, Maitra NU, Mellon JK, Khan MA. Defining prostate can-
cer risk before prostate biopsy. Urol Oncol. 2013;31(8):1408–18.
 151. Wang YH, Ji J, Wang BC, Chen H, Yang ZH, Wang K, et al. 
Tumor-derived exosomal long noncoding RNAs as promising 
diagnostic biomarkers for prostate cancer. Cell Physiol Biochem. 
2018;46(2):532–45.
 152. Thomson DW, Bracken CP, Goodall GJ. Experimental strate-
gies for microRNA target identification. Nucleic Acids Res. 
2011;39(16):6845–53.
 153. Berardocco M, Radeghieri A, Busatto S, Gallorini M, Raggi C, 
Gissi C, et al. RNA-seq reveals distinctive RNA profiles of small 
extracellular vesicles from different human liver cancer cell lines. 
Oncotarget. 2017;8(47):82920–399.
 154. Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, et al. LncR-
NADisease: a database for long-non-coding RNA-associated 
diseases. Nucleic Acids Res. 2013;41:D983–D986.
 155. Gong J, Liu W, Zhang J, Miao X, Guo AY. lncRNASNP: a data-
base of SNPs in lncRNAs and their potential functions in human 
and mouse. Nucleic Acids Res. 2015;43:D181–D186.
 156. Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, 
et al. miRTarBase update 2018: a resource for experimentally 
validated microRNA-target interactions. Nucleic Acids Res. 
2018;46(D1):D296–302.
 157. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding 
miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction 
networks from large-scale CLIP-Seq data. Nucleic Acids Res. 
2014;42:D92–D97.
 158. Wessels HH, Lebedeva S, Hirsekorn A, Wurmus R, Aka-
lin A, Mukherjee N, et al. Global identification of functional 
microRNA-mRNA interactions in Drosophila. Nat Commun. 
2019;10(1):1626.
 159. Paraskevopoulou MD, Karagkouni D, Vlachos IS, Tastsoglou 
S, Hatzigeorgiou AG. microCLIP super learning framework 
uncovers functional transcriptome-wide miRNA interactions. 
Nat Commun. 2018;9(1):3601.
 160. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effec-
tive microRNA target sites in mammalian mRNAs. Elife. 
2015;4:e05005.
 161. Hanna J, Hossain GS, Kocerha J. The potential for microRNA 
therapeutics and clinical research. Front Genet. 2019;10:478.
 162. Mayr C, Bartel DP. Widespread shortening of 3’UTRs by alterna-
tive cleavage and polyadenylation activates oncogenes in cancer 
cells. Cell. 2009;138(4):673–84.
 163. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between 
let-7 and Hmga2 enhances oncogenic transformation. Science. 
2007;315(5818):1576–9.
 164. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses 
the HMGA2 oncogene. Genes Dev. 2007;21(9):1025–30.
 165. Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne 
JC, et al. Prognostic role of the LCS6 KRAS variant in locally 
advanced rectal cancer: results of the EXPERT-C trial. Ann 
Oncol. 2015;26(9):1936–41.
 166. Tan SB, Li J, Chen X, Zhang W, Zhang D, Zhang C, et al. Small 
molecule inhibitor of myogenic microRNAs leads to a discov-
ery of miR-221/222-myoD-myomiRs regulatory pathway. Chem 
Biol. 2014;21(10):1265–70.
 167. Monroig Pdel C, Chen L, Zhang S, Calin GA. Small molecule 
compounds targeting miRNAs for cancer therapy. Adv Drug 
Deliv Rev. 2015;81:104–16.
Non-Coding RNA-Based Therapeutics
 168. Zhang S, Chen L, Jung EJ, Calin GA. Targeting microRNAs with 
small molecules: from dream to reality. Clin Pharmacol Ther. 
2010;87(6):754–8.
 169. Wen D, Danquah M, Chaudhary AK, Mahato RI. Small mol-
ecules targeting microRNA for cancer therapy: promises and 
obstacles. J Control Release. 2015;219:237–47.
 170. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, 
Deiters A. Small-molecule inhibitors of microrna miR-21 func-
tion. Angew Chem Int Ed Engl. 2008;47(39):7482–4.
 171. Young DD, Connelly CM, Grohmann C, Deiters A. Small 
molecule modifiers of microRNA miR-122 function for the 
treatment of hepatitis C virus infection and hepatocellular car-
cinoma. J Am Chem Soc. 2010;132(23):7976–81.
 172. Piroozian F, Bagheri Varkiyani H, Koolivand M, Ansari M, 
Afsa M, AtashAbParvar A, et al. The impact of variations in 
transcription of DICER and AGO2 on exacerbation of child-
hood B-cell lineage acute lymphoblastic leukaemia. Int J Exp 
Pathol. 2019;100(3):184–91.
 173. Essandoh K, Yang L, Wang X, Huang W, Qin D, Hao J, et al. 
Blockade of exosome generation with GW4869 dampens the 
sepsis-induced inflammation and cardiac dysfunction. Biochim 
Biophys Acta. 2015;1852(11):2362–71.
 174. Riches A, Campbell E, Borger E, Powis S. Regulation 
of exosome release from mammary epithelial and breast 
cancer cells—a new regulatory pathway. Eur J Cancer. 
2014;50(5):1025–34.
 175. Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, 
Sayan AE, et al. Exosomal microRNAs (exomiRs): small mol-
ecules with a big role in cancer. Cancer Lett. 2018;420:228–35.
 176. Guay C, Kruit JK, Rome S, Menoud V, Mulder NL, Jurdzinski 
A, et al. Lymphocyte-derived exosomal microRNAs promote 
pancreatic beta cell death and may contribute to type 1 diabetes 
development. Cell Metab. 2019;29(2):348–61.e6.
 177. Kosgodage US, Mould R, Henley AB, Nunn AV, Guy GW, 
Thomas EL, et al. Cannabidiol (CBD) is a novel inhibitor for 
exosome and microvesicle (EMV) release in cancer. Front Phar-
macol. 2018;9:889.
 178. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibili-
ties. RNA. 2010;16(11):2043–50.
 179. Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, 
Hearn S, et al. Differentiation of mammary tumors and reduc-
tion in metastasis upon Malat1 lncRNA loss. Genes Dev. 
2016;30(1):34–51.
 180. Li Z, Li X, Chen X, Li S, Ho IHT, Liu X, et al. Emerging roles 
of long non-coding RNAs in neuropathic pain. Cell Prolif. 
2019;52(1):e12528.
 181. Lee JS, Mendell JT. Antisense-mediated transcript knock-
down triggers premature transcription termination. Mol Cell. 
2020;77(5):1044–54.e3.
 182. Koch L. Functional genomics: screening for lncRNA function. 
Nat Rev Genet. 2017;18(2):70.
 183. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, 
Whitehead EH, et al. Genome-scale CRISPR-mediated control 
of gene repression and activation. Cell. 2014;159(3):647–61.
 184. Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He 
D, et al. CRISPRi-based genome-scale identification of func-
tional long noncoding RNA loci in human cells. Science. 
2017;355(6320):7111.
 185. Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, 
Nakamura M, et al. Antisense transcription in the mammalian 
transcriptome. Science. 2005;309(5740):1564–6.
 186. Ideue T, Hino K, Kitao S, Yokoi T, Hirose T. Efficient oligonu-
cleotide-mediated degradation of nuclear noncoding RNAs in 
mammalian cultured cells. RNA. 2009;15(8):1578–87.
 187. Endo H, Shiroki T, Nakagawa T, Yokoyama M, Tamai K, Yama-
nami H, et al. Enhanced expression of long non-coding RNA 
HOTAIR is associated with the development of gastric cancer. 
PLoS ONE. 2013;8(10):e77070.
 188. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA 
interference and antisense oligonucleotides. Nat Rev Drug Dis-
cov. 2012;11(2):125–40.
 189. Houseley J, Tollervey D. The many pathways of RNA degrada-
tion. Cell. 2009;136(4):763–76.
 190. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen 
K, Breen W, et  al. Potent and persistent in  vivo anti-HBV 
activity of chemically modified siRNAs. Nat Biotechnol. 
2005;23(8):1002–7.
 191. Deleavey GF, Damha MJ. Designing chemically modified 
oligonucleotides for targeted gene silencing. Chem Biol. 
2012;19(8):937–54.
 192. Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic 
Acids Res. 2016;44(14):6518–48.
 193. Sehgal A, Vaishnaw A, Fitzgerald K. Liver as a target for oligo-
nucleotide therapeutics. J Hepatol. 2013;59(6):1354–9.
 194. Srinivasan SK, Tewary HK, Iversen PL. Characterization of bind-
ing sites, extent of binding, and drug interactions of oligonucleo-
tides with albumin. Antisense Res Dev. 1995;5(2):131–9.
 195. Sharma VK, Watts JK. Oligonucleotide therapeutics: chem-
istry, delivery and clinical progress. Future Med Chem. 
2015;7(16):2221–42.
 196. Bai ZM, Wei J, Yu CM, Han XS, Qin XF, Zhang CW, et al. 
Non-viral nanocarriers for intracellular delivery of microRNA 
therapeutics. J Mater Chem B. 2019;7(8):1209–25.
 197. Li Z, Rana TM. Therapeutic targeting of microRNAs: cur-
rent status and future challenges. Nat Rev Drug Discov. 
2014;13(8):622–38.
 198. Orellana EA, Tenneti S, Rangasamy L, Lyle LT, Low PS, 
Kasinski AL. FolamiRs: ligand-targeted, vehicle-free delivery 
of microRNAs for the treatment of cancer. Sci Transl Med. 
2017;9(401):9327.
 199. Zhang Z, Wang J, Tacha DE, Li P, Bremer RE, Chen H, 
et  al. Folate receptor alpha associated with triple-negative 
breast cancer and poor prognosis. Arch Pathol Lab Med. 
2014;138(7):890–5.
 200. Cagle PT, Zhai QJ, Murphy L, Low PS. Folate receptor in adeno-
carcinoma and squamous cell carcinoma of the lung: potential 
target for folate-linked therapeutic agents. Arch Pathol Lab Med. 
2013;137(2):241–4.
 201. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon 
CP. Folate receptor expression in carcinomas and normal tis-
sues determined by a quantitative radioligand binding assay. Anal 
Biochem. 2005;338(2):284–93.
 202. Yang J, Vlashi E, Low P. Folate-linked drugs for the treat-
ment of cancer and inflammatory diseases. Subcell Biochem. 
2012;56:163–79.
 203. Batrakova EV, Kim MS. Using exosomes, naturally-
equipped nanocarriers, for drug delivery. J Control Release. 
2015;219:396–405.
 204. Syn NL, Wang L, Chow EK, Lim CT, Goh BC. Exosomes in 
cancer nanomedicine and immunotherapy: prospects and chal-
lenges. Trends Biotechnol. 2017;35(7):665–76.
 205. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuy-
ama N, et al. Systemically injected exosomes targeted to EGFR 
deliver antitumor microRNA to breast cancer cells. Mol Ther. 
2013;21(1):185–91.
 206. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der 
Veer E, et al. In vitro antiviral activity and preclinical and clini-
cal resistance profile of miravirsen, a novel anti-hepatitis C virus 
therapeutic targeting the human factor miR-122. Antimicrob 
Agents Chemother. 2015;59(1):599–608.
 207. Querfeld C, Pacheco T, Foss FM, Halwani AS, Porcu P, Seto AG, 
et al. Preliminary results of a phase 1 trial evaluating MRG-106, 
 M. Ratti et al.
a synthetic microRNA antagonist (LNA antimiR) of micro-
RNA-155, in patients with CTCL. Blood. 2016;128(22):1829.
 208. Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic 
M, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, 
co-ordinately regulates multiple survival pathways to reduce cel-
lular proliferation and survival in cutaneous T-cell lymphoma. 
Br J Haematol. 2018;183(3):428–44.
 209. Gallant-Behm CL, Piper J, Dickinson BA, Dalby CM, Pestano 
LA, Jackson AL. A synthetic microRNA-92a inhibitor (MRG-
110) accelerates angiogenesis and wound healing in diabetic and 
nondiabetic wounds. Wound Repair Regen. 2018;26(4):311–23.
 210. Kreth S, Hubner M, Hinske LC. MicroRNAs as clinical bio-
markers and therapeutic tools in perioperative medicine. Anesth 
Analg. 2018;126(2):670–81.
 211. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, 
Paulin RP, et al. Bacterially derived 400 nm particles for encap-
sulation and cancer cell targeting of chemotherapeutics. Cancer 
Cell. 2007;11(5):431–45.
 212. Gallant-Behm CL, Piper J, Lynch JM, Seto AG, Hong SJ, Mustoe 
TA, et al. A MicroRNA-29 mimic (Remlarsen) represses extra-
cellular matrix expression and fibroplasia in the skin. J Invest 
Dermatol. 2019;139(5):1073–81.
 213. Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola 
J, et al. Human glioma growth is controlled by microRNA-10b. 
Cancer Res. 2011;71(10):3563–72.
 214. Monroig-Bosque PD, Rivera CA, Calin GA. MicroRNAs in can-
cer therapeutics: "from the bench to the bedside". Expert Opin 
Biol Th. 2015;15(10):1381–5.
 215. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan 
M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. 
Nature. 2011;474(7353):649–53.
 216. Motavaf M, Safari S, Alavian SM. Targeting microRNA-122: 
walking on cutting edge of hepatitis C virus infection therapy. 
Acta Virol. 2014;58(4):301–8.
 217. van der Ree MH, de Vree JM, Stelma F, Willemse S, van 
der Valk M, Rietdijk S, et  al. Safety, tolerability, and anti-
viral effect of RG-101 in patients with chronic hepatitis C: a 
phase 1B, double-blind, randomised controlled trial. Lancet. 
2017;389(10070):709–17.
 218. Gomez IG, MacKenna DA, Johnson BG, Kaimal V, Roach AM, 
Ren S, et al. Anti-microRNA-21 oligonucleotides prevent Alport 
nephropathy progression by stimulating metabolic pathways. J 
Clin Invest. 2015;125(1):141–56.
 219. Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, et al. 
MicroRNA-21 promotes fibrosis of the kidney by silencing meta-
bolic pathways. Sci Transl Med. 2012;4(121):121.
 220. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung 
G, et al. The noncoding RNA MALAT1 is a critical regulator 
of the metastasis phenotype of lung cancer cells. Cancer Res. 
2013;73(3):1180–9.
 221. Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 
2015;21(11):1253–61.
 222. Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, 
et al. Effects of a novel long noncoding RNA, lncUSMycN, on 
N-Myc expression and neuroblastoma progression. J Natl Cancer 
Inst. 2014;106(7):113.
 223. Zhuo W, Liu Y, Li S, Guo D, Sun Q, Jin J, et al. Long noncoding 
RNA GMAN, up-regulated in gastric cancer tissues, is associated 
with metastasis in patients and promotes translation of ephrin 
A1 by competitively binding GMAN-AS. Gastroenterology. 
2019;156(3):676–91.e11.
 224. Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev 
P, et al. p53 induces formation of NEAT1 lncRNA-containing 
paraspeckles that modulate replication stress response and che-
mosensitivity. Nat Med. 2016;22(8):861–8.
 225. Gofrit ON, Benjamin S, Halachmi S, Leibovitch I, Dotan Z, 
Lamm DL, et al. DNA based therapy with diphtheria toxin-
A BC-819: a phase 2b marker lesion trial in patients with 
intermediate risk nonmuscle invasive bladder cancer. J Urol. 
2014;191(6):1697–702.
 226. Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, 
Appelbaum L, et al. Phase 1/2a, dose-escalation, safety, pharma-
cokinetic and preliminary efficacy study of intratumoral adminis-
tration of BC-819 in patients with unresectable pancreatic cancer. 
Cancer Gene Ther. 2012;19(6):374–81.
 227. Hasenpusch G, Pfeifer C, Aneja MK, Wagner K, Reinhardt D, 
Gilon M, et al. Aerosolized BC-819 inhibits primary but not 
secondary lung cancer growth. PLoS ONE. 2011;6(6):e20760.
 228. Lavie O, Edelman D, Levy T, Fishman A, Hubert A, Segev Y, 
et al. A phase 1/2a, dose-escalation, safety, pharmacokinetic, and 
preliminary efficacy study of intraperitoneal administration of 
BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal 
cancer. Arch Gynecol Obstet. 2017;295(3):751–61.
 229. Sidi AA, Ohana P, Benjamin S, Shalev M, Ransom JH, Lamm D, 
et al. Phase I/II marker lesion study of intravesical BC-819 DNA 
plasmid in H19 over expressing superficial bladder cancer refrac-
tory to bacillus Calmette-Guerin. J Urol. 2008;180(6):2379–83.
 230. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the 
H19 gene regulatory sequences and diphtheria toxin A, for 
the potential targeted therapy of cancers. Curr Opin Mol Ther. 
2010;12(5):607–16.
 231. Sorin V, Ohana P, Gallula J, Birman T, Matouk I, Hubert A, 
et  al. H19-promoter-targeted therapy combined with gem-
citabine in the treatment of pancreatic cancer. ISRN Oncol. 
2012;2012:351750.
 232. Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, 
Ueda M, Kristen AV, et  al. Patisiran, an RNAi therapeu-
tic, for hereditary transthyretin amyloidosis. N Engl J Med. 
2018;379(1):11–21.
 233. Yang J. Patisiran for the treatment of hereditary transthyre-
tin-mediated amyloidosis. Expert Rev Clin Pharmacol. 
2019;12(2):95–9.
 234. Petrovic N, Ergun S, Isenovic ER. Levels of microRNA hetero-
geneity in cancer biology. Mol Diagn Ther. 2017;21(5):511–23.
 235. Lv D, Wang X, Dong J, Zhuang Y, Huang S, Ma B, et al. System-
atic characterization of lncRNAs’ cell-to-cell expression hetero-
geneity in glioblastoma cells. Oncotarget. 2016;7(14):18403–14.
 236. van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van 
Vliet A, Welzel TM, et al. Long-term safety and efficacy of 
microRNA-targeted therapy in chronic hepatitis C patients. Anti-
viral Res. 2014;111:53–9.
